Gilead Sciences, Inc. (GILD)
After hours:
| Previous Close | 67.86 |
| Open | 67.77 |
| Bid | 67.72 x 200 |
| Ask | 67.76 x 200 |
| Day's Range | 67.21 - 67.82 |
| 52 Week Range | 64.33 - 87.87 |
| Volume | |
| Avg. Volume | 7,023,758 |
| Market Cap | 84.369B |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | 188.11 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.08 (4.54%) |
| Ex-Dividend Date | Jun 14, 2024 |
| 1y Target Est | N/A |
- Business Wire
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
- ACCESSWIRE
Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care
NORTHAMPTON, MA / ACCESSWIRE / May 14, 2024 / Olivia Sloan was pursuing a career in health policy and research when her father was diagnosed with non-Hodgkin lymphoma. The devastating news put her work on hold as she returned home to Santa Fe, New ...
- Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
